Glaxo Sells Bad With Good in Safety Push Amid China Woes
This article is for subscribers only.
When 100 of the top lung doctors in the U.S. gathered at a Hilton hotel in Houston last month to learn about GlaxoSmithKline Plc’s new respiratory drug, one message rang loud and clear: don’t ignore the pneumonia risk.
Much of the two-day meeting, organized by Glaxo, was devoted to potential side effects of the medicine, called Breo, which went on sale in the U.S. on Oct 30. The shift in emphasis is part of a shakeup at the U.K. drugmaker, which remains the focus of a bribery probe in China on the heels of a settlement last year in the U.S. to pay a record $3-billion fine for illegally marketing medicines.